| Immunic to Participate in Scientific and Industry Conferences in May |
NEW YORK , May 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in May: May 3-6: Digestive Disease Week (DDW). Two abstracts discussing Immunic's phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), in patients with celiac disease, have been accepted for poster presentations at this conference in San Diego, CA. |
prnewswire.com |
2025-05-02 10:30:00 |
Czytaj oryginał (ang.) |
| Immunic reports reduced disability worsening in progressive multiple sclerosis trial |
Immunic Inc (NASDAQ:IMUX) has reported promising results from its Phase 2 CALLIPER trial of vidofludimus calcium, which showed a 30% reduction in the risk of 24-week confirmed disability worsening in patients with primary progressive multiple sclerosis (PPMS) compared to placebo. The study enrolled 467 patients with progressive multiple sclerosis (PMS), including subpopulations with PPMS and non-active secondary progressive multiple sclerosis. |
proactiveinvestors.com |
2025-04-30 13:36:25 |
Czytaj oryginał (ang.) |
| Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial |
– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Primary Progressive Multiple Sclerosis – – Showed Consistent Reduction of Disability Worsening in Subpopulations Without Inflammatory Lesions at Baseline in Overall Study Population; Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events in Patients Without Gadolinium-Enhancing Lesions at Baseline by 29% Compared to Placebo – – Reduced Annualized Rate of Thalamic Brain Volume Loss by 20% Compared to Placebo – – Confirmed Favorable Safety and Tolerability Observed in Previous Clinical Trials; No New Safety Signals Identified – – Webcast to be Held Today, April 30, at 8:00 am ET – NEW YORK , April 30, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS). Clinical Endpoints In the overall PMS patient population (n=467), vidofludimus calcium reduced the relative risk of 24-week confirmed disability worsening (24wCDW) events based on changes in the expanded disability status scale (EDSS) by 20% compared to placebo. |
prnewswire.com |
2025-04-30 11:30:00 |
Czytaj oryginał (ang.) |
| Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher |
Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results and potential for commercialization if upcoming catalysts deliver. Despite high volatility and recent stock dilution, Immunic's market cap remains low, suggesting significant upside if clinical trials succeed. Vidofludimus calcium's unique dual action offers neuroprotection and anti-inflammatory benefits, positioning it as a potential next-gen oral MS treatment. |
seekingalpha.com |
2025-04-28 06:09:56 |
Czytaj oryginał (ang.) |
| Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments |
NEW YORK , April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced registered direct offering of 5,666,667 shares of its common stock at a price of $0.90 per share, led by Aberdeen Investments. All securities in the offering were sold by Immunic. |
prnewswire.com |
2025-04-10 17:00:00 |
Czytaj oryginał (ang.) |
| Immunic announces pricing of $5.1M direct offering to support clinical pipeline |
Immunic Inc (NASDAQ:IMUX) has priced its $5.1 million registered direct offering led by Aberdeen Investments, selling 5.67 million shares at $0.90 each. The biotechnology company, which is advancing orally administered therapies for chronic inflammatory and autoimmune diseases, expects the financing to close around April 10. |
proactiveinvestors.com |
2025-04-09 12:53:49 |
Czytaj oryginał (ang.) |
| Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments |
NEW YORK , April 9, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of a registered direct offering of 5,666,667 shares of its common stock at the market under Nasdaq rules at a price of $0.90 per share, led by Aberdeen Investments. All securities in the offering are being sold by Immunic. |
prnewswire.com |
2025-04-09 12:10:00 |
Czytaj oryginał (ang.) |
| Immunic, Inc. to Participate in Scientific and Industry Conferences in April |
NEW YORK , April 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in April: April 5-9: American Academy of Neurology (AAN) 2025 Annual Meeting. Members of Immunic's management, medical and preclinical teams will attend this meeting in San Diego, California. |
prnewswire.com |
2025-04-01 10:30:00 |
Czytaj oryginał (ang.) |
| Immunic provides MS research update – ICYMI |
Immunic Inc (NASDAQ:IMUX) earlier this week provided an update on its multiple sclerosis (MS) drug, vidofludimus calcium, highlighting its potential to address both inflammation and neuroprotection. Dr Hella Kohlhof, Immunic's Chief Scientific Officer, explained that the drug works through a dual mode of action—activating Nurr1 for neuroprotection and inhibiting DHODH to reduce inflammation and Epstein-Barr virus reactivation. |
proactiveinvestors.com |
2025-03-14 18:29:54 |
Czytaj oryginał (ang.) |
| Immunic to Participate in Scientific and Investor Conferences in March |
NEW YORK , March 3, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March: March 4-7: 34th Annual Meeting of the Society for Virology. Two abstracts have been accepted for abstract talk presentations at this conference in Hamburg, Germany. |
prnewswire.com |
2025-03-03 08:30:00 |
Czytaj oryginał (ang.) |
| Biotechs challenge big pharma with new oral weight loss therapies |
With the smash success of glucagon-like peptide-1 (GLP-1) agonists as a treatment for obesity, pharmaceutical giants and emerging biotechnology firms alike are working to develop an equally effective option in the form of pills. The weight loss drug market, projected by Goldman Sachs to reach $130 billion by 2030, represents a significant opportunity for drugmakers. |
proactiveinvestors.com |
2025-02-28 13:44:24 |
Czytaj oryginał (ang.) |
| Immunic to highlight vidofludimus calcium's potential as MS therapy at upcoming forum |
Immunic Inc (NASDAQ:IMUX) announced that it will present key data for its investigational drug vidofludimus calcium in two poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025. "Having two poster presentations on vidofludimus calcium at the prestigious ACTRIMS Forum highlights the unique importance of our drug candidate and its promise as a potential new treatment option for multiple sclerosis (MS)," Immunic CEO Dr Daniel Vitt said in a statement. |
proactiveinvestors.com |
2025-02-26 10:43:00 |
Czytaj oryginał (ang.) |
| Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis |
– Vidofludimus Calcium's Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activation s in Preclinical Models – – Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – NEW YORK , Feb. 26, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data on its lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in two poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025, taking place from February 27 to March 1, in West Palm Beach, Florida. "Having two poster presentations on vidofludimus calcium at the prestigious ACTRIMS Forum highlights the unique importance of our drug candidate and its promise as a potential new treatment option for multiple sclerosis (MS)," stated Daniel Vitt, Ph.D. |
prnewswire.com |
2025-02-26 08:30:00 |
Czytaj oryginał (ang.) |
| Immunic drug candidate may offer new obesity treatment - ICYMI |
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive to discuss the company's latest findings on IMU-856, a drug candidate initially studied for celiac disease. New data suggests that IMU-856 significantly increases endogenous GLP-1 levels in a dose-dependent manner, which could make it a potential oral treatment for obesity. |
proactiveinvestors.com |
2025-02-22 10:41:54 |
Czytaj oryginał (ang.) |
| Immunic highlights IMU-856's potential as weight management therapy |
Immunic Inc (NASDAQ:IMUX) has released new data that supports the potential of its investigational therapeutic IMU-856 as an oral treatment for weight management. IMU-856, a small molecule that targets SIRT6, demonstrated a dose-dependent increase in endogenous glucagon-like peptide-1 (GLP-1) levels in a post hoc analysis of patients from a phase 1b clinical trial in celiac disease. |
proactiveinvestors.com |
2025-02-20 12:02:05 |
Czytaj oryginał (ang.) |
| Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing |
– New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready – – Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Post Hoc Analysis of Patients From Phase 1b Clinical Trial in Celiac Disease – – Dose-Dependent Reduction of Body Weight Gain and Food Consumption Observed in Preclinical Study – – Webcast to be Held Today, February 20 at 8:00 am ET – NEW YORK , Feb. 20, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), demonstrated a dose-dependent increase of endogenous glucagon-like peptide-1 (GLP-1) levels in a post hoc analysis of patients from its phase 1b clinical trial in celiac disease. IMU-856 also showed a dose-dependent reduction of body weight gain and food consumption in preclinical in vivo testing. |
prnewswire.com |
2025-02-20 09:30:00 |
Czytaj oryginał (ang.) |
| Immunic to Participate in Investor and Scientific Conferences in February |
NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February: February 10-11: BIO CEO & Investor Conference 2025. Daniel Vitt, Ph.D. |
prnewswire.com |
2025-02-04 08:30:00 |
Czytaj oryginał (ang.) |
| Immunic eyes transformative year ahead for MS therapy vidofludimus calcium - ICYMI |
Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio joined Proactive to discuss the company's progress in advancing its novel therapy vidofludimus calcium. He discussed the significant milestones achieved in 2024, such as the positive interim analysis of the ENSURE trials in relapsing multiple sclerosis (MS) and the anticipation of the results from the CALLIPER progressive MS study in April 2025. |
proactiveinvestors.com |
2025-01-11 11:22:10 |
Czytaj oryginał (ang.) |
| Immunic eyes key data readout from multiple sclerosis trial in 2025 |
Immunic Inc (NASDAQ:IMUX) has reflected on key milestones achieved in 2024, including advancing its novel therapy, vidofludimus calcium, toward key data readouts and securing significant funding to progress its clinical programs. In a statement, the company said it expects top-line data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (PMS) in April 2025. |
proactiveinvestors.com |
2025-01-07 11:19:17 |
Czytaj oryginał (ang.) |
| Immunic Highlights 2024 Accomplishments and Upcoming Milestones |
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 – – Strengthened Management Team and Board of Directors with Key Hires – – Announced a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today highlighted its 2024 accomplishments and upcoming milestones. "The past year was marked by substantial progress for our orally available lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), as we continued to advance both our phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and our twin phase 3 ENSURE trials in relapsing multiple sclerosis (RMS)," stated Daniel Vitt, Ph.D. |
prnewswire.com |
2025-01-07 08:30:00 |
Czytaj oryginał (ang.) |
| Immunic, Inc. to Participate in Investor Conference in December |
NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 5, 2024, at 11:30 am ET, during the Piper Sandler 36th Annual Healthcare Conference, taking place December 3-5, 2024, in New York. |
prnewswire.com |
2024-11-26 08:30:00 |
Czytaj oryginał (ang.) |
| Immunic's IMU-856 shows potential in gastrointestinal health trials - ICYMI |
Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr. Andreas Muehler talked with Proactive about the publication of the company's Phase 1 and Phase 1b clinical trial results for IMU-856 in The Lancet Gastroenterology & Hepatology. |
proactiveinvestors.com |
2024-11-16 14:59:52 |
Czytaj oryginał (ang.) |
| Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet |
Immunic Inc (NASDAQ:IMUX) announced that data from its phase 1/1b clinical trial for IMU-856, a small molecule targeting SIRT6, has been published in The Lancet Gastroenterology & Hepatology. The study, led by Dr James Daveson, a gastroenterologist with Wesley Research Institute in Australia, evaluated IMU-856's safety and efficacy in patients with celiac disease. |
proactiveinvestors.com |
2024-11-13 11:39:21 |
Czytaj oryginał (ang.) |
| Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology |
– Includes Phase 1 Data in Healthy Human Subjects and Phase 1b Data in Celiac Disease Patients – NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the data from its phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), has been published in the peer reviewed journal, The Lancet Gastroenterology & Hepatology. Lead authored by Dr. A. |
prnewswire.com |
2024-11-13 08:30:00 |
Czytaj oryginał (ang.) |
| Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript |
Immunic, Inc. (NASDAQ:IMUX ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Jessica Breu - Vice President Investor Relations and Communications Daniel Vitt - Chief Executive Officer and Director Glenn Whaley - Chief Financial Officer Jason Tardio - President and Chief Operating Officer Conference Call Participants William Wood - B. Riley Matt Cowper - Leerink Partners Matt Kaplan - Ladenburg Operator Good morning, and welcome to Immunic's Third Quarter 2024 Earnings Call. |
seekingalpha.com |
2024-11-09 10:37:08 |
Czytaj oryginał (ang.) |
| Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones |
Immunic Inc (NASDAQ:IMUX) ended the third quarter with over $59 million in cash to advance its key clinical programs, including its lead candidate, vidofludimus calcium (IMU-838), for multiple sclerosis (MS). During the third quarter ended September 30, 2024, the firm advanced both its phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and a twin phase 3 ENSURE trials in relapsing multiple sclerosis (RMS) looking at orally available lead asset, nuclear receptor related 1 (Nurr1) activator, IMU-838. |
proactiveinvestors.com |
2024-11-07 10:58:15 |
Czytaj oryginał (ang.) |
| Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
– Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should Continue as Planned – – Ongoing, Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Remain on Track – – Top-Line Data from Phase 2 CALLIPER Trial Expected in April 2025 – – Webcast to be Held Today, November 7, at 8:00 am ET – NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the third quarter and nine months ended September 30, 2024, and provided a corporate update. "During the third quarter, we have continued to advance both our phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and our twin phase 3 ENSURE trials in relapsing multiple sclerosis (RMS), for our potentially transformative, orally available lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838)," stated Daniel Vitt, Ph.D. |
prnewswire.com |
2024-11-07 08:30:00 |
Czytaj oryginał (ang.) |
| Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update |
– Webcast to be Held at 8:00 am ET on November 7, 2024 – NEW YORK , Oct. 31, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2024, including a corporate update, on Thursday, November 7, 2024, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET. |
prnewswire.com |
2024-10-31 08:30:00 |
Czytaj oryginał (ang.) |
| Immunic to Participate in Industry, Scientific and Investor Conferences in November |
NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry, scientific and investor conferences in November: November 4-6: BIO-Europe. Members of Immunic's management, business development and investor relations teams will participate in partnering activities at this conference in Stockholm, Sweden. |
prnewswire.com |
2024-10-29 08:30:00 |
Czytaj oryginał (ang.) |
| Immunic Phase 3 MS study advances following positive recommendation from independent committee |
Immunic Inc (NASDAQ:IMUX) announced a positive outcome from the interim futility analysis of its Phase 3 ENSURE program which is investigating its lead asset vidofludimus calcium in relapsing multiple sclerosis (RMS). The company said an Independent Data Monitoring Committee (IDMC) reviewed unblinded data and concluded that the trials had not met futility criteria, recommending that the study continue as planned without any changes. |
proactiveinvestors.com |
2024-10-22 13:16:21 |
Czytaj oryginał (ang.) |
| Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis |
– Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermined Futility Criteria Have Not Been Met – – IDMC Also Recommended Continuing Trial without Changes, Including no Need for a Potential Upsizing – – ENSURE Program Remains on Track to be Completed in 2026 – – Webcast to be Held Today, October 22, at 8:00 am ET – NEW YORK , Oct. 22, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced a positive outcome of the non-binding, interim futility analysis of its phase 3 ENSURE program, investigating lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), for the treatment of relapsing multiple sclerosis (RMS). Based on the outcome of the interim futility analysis, an unblinded Independent Data Monitoring Committee (IDMC) has recommended that the trials are not futile and should continue as planned. |
prnewswire.com |
2024-10-22 10:30:00 |
Czytaj oryginał (ang.) |
| Immunic highlights lead asset's promise in multiple sclerosis at ECTRIMS Congress |
Immunic Inc (NASDAQ:IMUX) announced that it is presenting key data for its lead asset vidofludimus calcium at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which has highlighted its therapeutic potential in multiple sclerosis (MS). Vidofludimus calcium consistently reduced neurofilament light chain (NfL) levels in the Phase 2 CALLIPER trial, suggesting it may slow disease progression across all progressive MS subtypes, the company reported. |
proactiveinvestors.com |
2024-09-18 12:43:28 |
Czytaj oryginał (ang.) |
| Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis |
– Vidofludimus Calcium Consistently Reduce d Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All Progressive Multiple Sclerosis Subtypes – – Clinical Signal Shown for Vidofludimus Calcium on Post COVID Fatigue May Be Related to Epstein-Barr Virus Reactivation; Preventing This Reactivation May Contribute to Fatigue Reduction in M ultiple Sclerosis Patients – – Preclinical Data Showed Improved Neuronal Survival, Likely Driven by Vidofludimus Calcium's Induction of Nurr1 Activation, as Demonstrated by Primary Target Gene Regulation – – In Preclinical Experiments, Vidofludimus Calcium Reduced or Prevented Development of Pathogenic Peripheral T Helper Cells, Which Could be One of the Treatment Pathways in Multiple Sclerosis – NEW YORK , Sept. 18, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of key data at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), highlighting Immunic's lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium's (IMU-838) therapeutic potential in multiple sclerosis (MS). |
prnewswire.com |
2024-09-18 10:30:00 |
Czytaj oryginał (ang.) |
| Immunic drug targeting post-COVID syndrome in Phase 2 trial - ICYMI |
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler joined Proactive to discuss a research update for the company's lead compound vidofludimus calcium. Vidofludimus calcium is being supplied for an investigator-sponsored Phase 2 clinical trial focused on treating post-COVID syndrome (PCCS). |
proactiveinvestors.com |
2024-09-07 12:30:49 |
Czytaj oryginał (ang.) |
| Immunic reports first patient enrolled in investigator-sponsored post-COVID syndrome trial |
Immunic Inc (NASDAQ:IMUX) announced that the first patient has been enrolled in an investigator-sponsored Phase 2 trial of its lead asset vidofludimus calcium for post-COVID syndrome. The RAPID_REVIVE study is sponsored by Goethe University Frankfurt, Germany, with funding received via a grant from the German Federal Ministry of Education and Research. |
proactiveinvestors.com |
2024-09-04 12:44:37 |
Czytaj oryginał (ang.) |
| Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome |
– Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided by Immunic – – In Addition to Post COVID Readouts, Study Designed to Deliver Important Data on the Activity of Vidofludimus Calcium Suppressing Epstein-Barr Virus Reactivation and Related Fatigue Symptoms; Third-Party Research Identified Epstein-Barr Virus R eactivation as Potential Cause for Post COVID Fatigue – – Severe Fatigue Also a Common and Debilitating Symptom for Multiple Sclerosis Patients with No Effective Therapies Available; Potential Read-Through to Immunic's Multiple Sclerosis Development Program – NEW YORK , Sept. 4, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced enrollment of the first patient in an investigator-sponsored phase 2 clinical trial of its lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), entitled, "Randomized Adaptive Assessment of Post COVID Syndrome Treatments_Reducing Inflammatory Activity in Patients with Post COVID Syndrome (RAPID_REVIVE). |
prnewswire.com |
2024-09-04 10:30:00 |
Czytaj oryginał (ang.) |
| Immunic to highlight lead asset's promise at upcoming Multiple Sclerosis R&D Day |
Immunic Inc (NASDAQ:IMUX) announced that it will be hosting a Multiple Sclerosis (MS) Research and Development (R&D) Day on September 10 featuring discussions on the company's lead drug asset vidofludimus calcium potential as a treatment for both relapsing and progressive MS patients. The company's management team, including CEO Daniel Vitt, COO Jason Tardio, chief medical officer Andreas Muehler, and chief scientific officer Hella Kohlhof will be joined by MS industry experts to discuss the MS space and vidofludimus calcium's promise. |
proactiveinvestors.com |
2024-08-28 13:41:54 |
Czytaj oryginał (ang.) |
| Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September |
NEW YORK , Aug. 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following scientific and investor conferences in September: September 10: Immunic's MS R&D Day. Management of Immunic, including Daniel Vitt, Ph.D. |
prnewswire.com |
2024-08-28 10:30:00 |
Czytaj oryginał (ang.) |
| Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript |
Immunic, Inc. (NASDAQ:IMUX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Jessica Breu - VP, IR & Communications Daniel Vitt - CEO Glenn Whaley - CFO Jason Tardio - COO Conference Call Participants Yasmeen Rahimi - Piper Sandler Matt Kaplan - Ladenburg Thalmann Tom Smith - Leerink Partners Tyler Bussian - Brookline Madison El-Saadi - B. Riley Jessica Breu Good morning, and welcome to Immunic's Second Quarter 2024 Earnings Call. |
seekingalpha.com |
2024-08-09 22:55:25 |
Czytaj oryginał (ang.) |
| Immunic strengthens leadership team as MS trials advance toward key milestones |
Immunic Inc (NASDAQ:IMUX) has highlighted clinical and operational progress achieved during the second quarter, which ended June 30, 2024, and the subsequent period. The biotechnology firm has welcomed experienced multiple sclerosis drug commercialization executive Jason Tardio as its chief operating officer and president and appointed senior pharmaceutical executive Simona Skerjanec to its board of directors. |
proactiveinvestors.com |
2024-08-08 13:10:41 |
Czytaj oryginał (ang.) |